Genetics consortiums can offer views facilitating best practice in Alzheimer's diseaseBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7156.471 (Published 15 August 1998) Cite this as: BMJ 1998;317:471
- Simon Lovestone, Chair of United Kingdom Alzheimer's Disease Genetics Consortium
- Institute of Psychiatry, London SE5 8AF
EDITOR—Alzheimer's disease is often taken as an example of a disorder for which the impact of the new genetics will be met, 1 2 and it was with this in mind that the United Kingdom Alzheimer's Disease Genetics Consortium was formed. Members of the consortium are clinicians involved in both genetics and dementia care, academics, members of lay organisations, and representatives from pharmaceutical research; they meet to consider the consequences of the growing understanding of genetics in Alzheimer's disease. Through …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial